申请人:Zeneca Limited
公开号:US05714496A1
公开(公告)日:1998-02-03
Compounds of formula (I) and their pharmaceutically acceptable salts in which R.sup.1 is hydrogen or hydroxy; R.sup.2 is hydrogen; or R.sup.1 and R.sup.2 are joined together so that CR.sup.1 -CR.sup.2 is a double bond; X is selected from --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --C.tbd.C--, --CH.sub.2 O--, --CH.sub.2 NH--, --NHCH.sub.2 --, --CH.sub.2 CO--, --COCH.sub.2 --, --CH.sub.2 S-- and --SCH.sub.2 --; Ar.sup.1 is a phenylene moiety; Ar.sup.2 is a heteroaryl moiety; and wherein one or both of Ar.sup.1 and Ar.sup.2 may optionally bear one or more substituents independently selected from halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, di-alkylamino, N-alkylcarbamoyl, di-N,N-alkylcarbamoyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, halogeno-alkyl, carboxyalkyl and alkanoylamino; provided that when R.sup.1 is hydroxy, X is not selected from --NHCH.sub.2 -- and --SCH.sub.2 --; are inhibitors of squalene synthase and hence useful in treating medical conditions in which a lowering of cholesterol is beneficial, such as hypercholesterolemia and atherosclerosis. Processes for preparing these derivatives, pharmaceutical compositions containing them are also described together with their use in medicine.
化合物的化学式为(I),其药学上可接受的盐,其中R.sup.1是氢或羟基;R.sup.2是氢;或者R.sup.1和R.sup.2连接在一起,使得CR.sup.1-CR.sup.2是双键;X从--CH.sub.2 CH.sub.2 --,--CH.dbd.CH--,--C.tbd.C--,--CH.sub.2 O--,--CH.sub.2 NH--,--NHCH.sub.2 --,--CH.sub.2 CO--,--COCH.sub.2 --,--CH.sub.2 S--和--SCH.sub.2 --中选择;Ar.sup.1是苯基;Ar.sup.2是杂环芳基;其中Ar.sup.1和Ar.sup.2中的一个或两个可以选择性地带有一个或多个取代基,这些取代基独立地选择自卤素,羟基,氨基,硝基,氰基,羧基,氨基甲酰基,烷基,烯基,炔基,烷氧基,烷基氨基,双烷基氨基,N-烷基氨基甲酰基,双N,N-烷基氨基甲酰基,烷氧羰基,烷基硫基,烷基亚砜基,烷基磺酰基,卤代烷基,羧基烷基和脂肪酰胺基;但当R.sup.1是羟基时,X不选择自--NHCH.sub.2--和--SCH.sub.2--;这些化合物是角鲨烷合酶的抑制剂,因此可用于治疗降低胆固醇有益的医疗状况,如高胆固醇血症和动脉硬化。还描述了制备这些衍生物的过程,含有它们的制药组合物以及它们在医学上的应用。